Friday, July 05, 2024 12:55:00 PM
Recent EOLS News
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/28/2024 01:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/07/2024 01:45:54 AM
- Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 • Business Wire • 09/06/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:14:51 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/09/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 09:00:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:12:11 PM
- Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance • Business Wire • 07/31/2024 08:05:00 PM
- Evolus to Hold Investor Day on September 12, 2024 • Business Wire • 07/31/2024 12:00:00 PM
- Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia • Business Wire • 07/30/2024 12:00:00 PM
- Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference • Business Wire • 07/25/2024 12:00:00 PM
- Evolus to Report Second Quarter Financial Results on July 31, 2024 • Business Wire • 07/17/2024 12:00:00 PM
- Evolus Announces Appointment of Albert G. White III to Board of Directors • Business Wire • 07/01/2024 12:00:00 PM
- Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products • Business Wire • 06/24/2024 12:00:00 PM
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain • Business Wire • 06/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:05:21 PM
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/07/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:01:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 09:45:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 01:30:56 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/05/2024 09:22:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 08:25:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 09:53:10 PM
- Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting • Business Wire • 05/20/2024 12:30:00 PM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM